Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Editas Medicine, Inc.NASDAQ: EDIT

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 10.8% from a year ago

Cash & equivalents stood at $123.65M at the end of Q1 FY2026, down 10.8% from a year earlier and down 15.7% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.

Context

  • Cash & equivalents amounted to 82.8% of total assets at the end of Q1 FY2026, up 30.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -10.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$123.65M-15.7% QoQ
Last fiscal yearDec 2025
$146.65M+11.5% YoY
Year agoMar 2025
$138.69M-10.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.8%——
1 year+11.5%——
3-year CAGR+1.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
146.65M USD
Year-over-year change
+11.5%
4-year CAGR
-7.9%

Cash & Equivalents vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's Mar 2026 cash & equivalents of $123.65M is the 5th highest of the 9 companies compared; the peer median is $117.03M.
  • Its year-over-year change of -10.8% is the 5th highest of 9, against a peer median of -11.2%.
  • Cash & equivalents amounts to 82.8% of total assets for EDIT, versus a peer median of 17.6%.
EDIT Competitors Peer median
Cash & Equivalents for EDIT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BEAMBeam Therapeutics Inc.Jun 2026$219.83M -22.1%+8.2%15.9%
CRSPCRISPR Therapeutics AGSep 2026$192.03M -33.8%+18.8%7.5%
BNTCBenitec Biopharma Inc.Mar 2026$184.76M +78.4%+188.7%98.8%
NTLAIntellia Therapeutics, Inc.Mar 2026$134.7M +6.2%-33.3%17.8%
EDITEditas Medicine, Inc.Mar 2026$123.65M -10.8%+1.2%82.8%
DTILPrecision BioSciences, Inc.Mar 2026$99.37M +28.7%-16.4%69.1%
PRMEPrime Medicine, Inc.Mar 2026$64.11M -30.2%-30.5%21.8%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$49.61M -0.4%-18.0%17.4%
CRBUCaribou Biosciences, Inc.Mar 2026$12.06M -59.0%-40.4%8.1%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding EDIT) $117.03M-11.2%-17.2%17.6%

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents203.52M141.52M123.65M131.54M146.65M
Short-term Investments296.33M202.75M199.46M138.37M0
Net Receivables267K5.15M10.19M16.27M15.18M
Inventory00000
Other Current Assets07.34M7.53M3.14M2.07M
Total Current Assets507.31M356.75M340.83M289.32M163.9M
Property, Plant & Equipment (Net)43.29M59.22M45.71M47.05M19.66M
Goodwill00000
Intangible Assets00000
Long-term Investments120.07M93.1M104.02M3.88M2.7M
Tax Assets00000
Other Non-current Assets6.81M5.25M8.59M1.35M276K
Total Non-current Assets170.17M157.57M158.32M52.27M22.64M
Total Assets677.48M514.32M499.15M341.59M186.53M
Account Payables5.05M9.51M8.27M5.49M2.61M
Short-term Debt0012M011.03M
Tax Payables00000
Deferred Revenue11.33M8.22M8.22M11.22M44.51M
Other Current Liabilities10.16M10.14M(723K)21.99M(11.9M)
Total Current Liabilities46.88M60.11M63.22M77.23M46.25M
Long-term Debt000053.61M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)60.89M60.67M60.67M106.64M44.51M
Other Non-current Liabilities001.8M3.07M2.82M
Total Non-current Liabilities76.96M93.53M86.84M130.09M113M
Total Liabilities123.84M153.64M150.06M207.32M159.25M
Common Stock7K7K8K8K10K
Retained Earnings(857.7M)(1.08B)(1.23B)(1.47B)(1.63B)
Accumulated OCI(493K)(3.6M)198K268K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity553.64M360.68M349.1M134.27M27.29M
Total Debt26.38M43.95M48.54M35.03M76.71M
Net Debt(177.14M)(97.58M)(75.11M)(96.51M)(69.94M)

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.